Century Therapeutics Inc (IPSC) Stock AnalysisIPSCStock AnalysisCentury Therapeutics Inc

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Century Therapeutics (IPSC) is currently priced at $2.025, which is below the analyst price targets of $5 and $8, indicating potential upside. However, the RSI is at 42.983, suggesting it is approaching oversold territory but not yet a strong buy signal. The company has shown significant revenue growth with $109.2 million in Q1 2025, but it also reported a net loss of $21.6 million in Q1 2026. The main risk is the recent insider selling trend, which has increased by 179.43% over the last quarter, indicating potential lack of confidence among insiders. Overall, while there are positive indicators, the risks suggest a cautious approach rather than an outright buy at this moment.